AccScience Publishing / GTM / Online First / DOI: 10.36922/GTM025370073
BRIEF REPORT

Application of the Memorial Sloan Kettering Cancer Center Van Zee nomogram to a cohort of Algerian patients with breast tumours equal to or larger than 4 cm without clinical axillary invasion

Saïd Haddadi1,2* Mohamed Boukhene1,2 Widad Kouachi1,2 Abdelmalek Matari2,3 Sofiane Zatir1,2 Rezki Touati1,2 Hamida Guendouz2,4 Myriam Medjaher2,5 Assia Slimani2,6 Mohcen Boubnider2,7 Norah Graidia1,2
Show Less
1 Department of General Surgery, Central Hospital of the Army Dr Mohamed Seghir Nekkache, Algiers, Algeria
2 Faculty of Medicine, University of Health Sciences Dr. Youssef Al-Khatib, Ben Aknoun, Algiers, Algeria
3 Epidemiology Department, Regional Military Hospital of Blida, Blida, Algeria
4 General Surgery Department, Public Hospital Establishment Djilali Rahmouni, Algiers, Algeria
5 Nuclear Medicine Department, Central Hospital of the Army Dr Mohamed Seghir Nekkache, Algiers, Algeria
6 Department of Pathological Anatomy, Teaching Hospital Issad Hassani, Béni-Messous, Rue Ibrahim Hadjeras, Algiers, Algeria
7 Senology Department, Pierre and Marie Curie Center, Algiers, Algeria
Global Translational Medicine, 025370073 https://doi.org/10.36922/GTM025370073
Received: 12 September 2025 | Revised: 5 January 2026 | Accepted: 4 February 2026 | Published online: 16 June 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Axillary node status remains the most important prognostic factor in breast cancer, although axillary lymph node dissection (ALND) is increasingly questioned in patients with positive sentinel lymph nodes (SLN). The Memorial Sloan Kettering Cancer Center Van Zee nomogram may support decision-making regarding completion of ALND after positive SLN. This study evaluated the performance of the Van Zee model in 32 Algerian patients with cN0 breast cancer ≥ 4 cm (8 cT2 and 24 cT3) and positive SLN who underwent routine ALND. Using a 35% cut-off, the nomogram achieved 88.9% sensitivity, 78.2% specificity, and 84.3% accuracy, with positive and negative predictive values of 84.2% and 84.6%, respectively. The area under the receiver operating characteristic (ROC) curve was 0.85, indicating good discriminatory performance. Predictors of non-SLN involvement included lymphovascular invasion, luminal subtype, and a higher number of positive SLNs. Although predictive models for axillary invasion are well established, data from the Middle East and North Africa region remain limited. These findings suggest that the Van Zee nomogram is applicable to Algerian patients with breast tumours ≥ 4 cm without clinical axillary involvement. However, larger studies are required before definitive validation.

Keywords
Large breast tumours
Sentinel lymph node
Nomogram
Cut-off values
Funding
None.
Conflict of interest
The authors have no conflict of interest to declare.
References
  1. Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918-926. doi: 10.1001/jama.2017.11470
  2. Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10(10):1140-1151. doi: 10.1245/ASO.2003.03.015
  3. Haddadi S, Touati R. Ganglion sentinelle: Elargissement des indications aux tumeurs de plus de 03 cm sans envahissement axillaire clinique (Grands T2N0M0 et T3N0M0) [thesis]. Faculté de Médecine, Université d’Alger 1 Benyoucef Benkhedda; 2023.
  4. van den Hoven I, van Klaveren D, Voogd AC, Vergouwe Y, Tjan-Heijnen V, Roumen RMH. A Dutch prediction tool to assess the risk of additional axillary non-sentinel lymph node involvement in sentinel node-positive breast cancer patients. Clin Breast Cancer. 2016;16(2):123-130. doi: 10.1016/j.clbc.2015.09.003
  5. Van Lappara RFD, de Roos WK, Constant C, Bavelaar-Croon CDL, Barneveld PC, Bosscha K. A prospective validation study of sentinel lymph node biopsy in multicentric breast cancer: SMMaC trial. Eur J Surg Oncol. 2014;40:1250-1255. doi: 10.1016/j.ejso.2013.11.004
  6. Wu Q, Deng L, Jiang Y, Zhang H. Application of the machine-learning model to improve prediction of non-sentinel lymph node metastasis status among breast cancer patients. Front Surg. 2022;9:797377. doi: 10.3389/fsurg.2022.797377
  7. Sun S, Chen Y, Liu Y, et al. A multicenter cohort study on ultrasound-based deep learning nomogram for predicting post-neoadjuvant chemotherapy axillary lymph node status in breast cancer patients. Acad Radiol. 2025;32(3):1252- 1263. doi: 10.1016/j.acra.2024.09.065
  8. Reyal F, Belichard C, Rouzier R, et al. Non-sentinel lymph node metastasis prediction in breast cancer with metastatic sentinel lymph node: impact of molecular subtypes classification. PLoS ONE. 2012;7(10):e47390. doi: 10.1371/journal.pone.0047390
Share
Back to top
Global Translational Medicine, Electronic ISSN: 2811-0021 Print ISSN: 3060-8600, Published by AccScience Publishing